XSHE
300519
Market cap354mUSD
Oct 09, Last price
15.16CNY
1D
2.09%
1Q
21.38%
Jan 2017
-62.57%
IPO
56.85%
Name
Zhejiang Xinguang Pharmaceutical Co Ltd
Chart & performance
P/E
44.74
P/S
9.14
EPS
0.34
Div yield, %
2.02%
Shrs. gr., 5y
-0.19%
Rev. gr., 5y
-3.73%
Revenues
265m
-0.86%
Net income
54m
+7.58%
CFO
69m
+28.99%
Dividend
May 29, 20260.3 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Zhejiang Xinguang Pharmaceutical Co., Ltd. engages in the research and development, production, and sales of Chinese patent medicines, chemical medicines, and health food in China. It offers pharmaceutical products that cover respiratory, digestive, and urinary systems, as well as cardiovascular, cerebrovascular, trauma, and pediatric diseases. The company was incorporated in 1998 and is headquartered in Shengzhou, China.
Key people
Yuejun Wang
Executive Chairman of the Board, General Manager · since 2025
Binbin Xing
Chief Financial Officer, Director · since 2018
Zhuping Sun
Chief Marketing Officer · since 2024
Fuyin Qiu
Deputy General Manager, Director · since 2012
Yuanyang Jiang
Deputy General Manager, Secretary of the Board, Director · since 2016
Yuyang Ma
Director · since 2024
Xiaolin Xing
Director · since 2018
Independent Director · since 2024
Guiyuan Lu
Independent Director · since 2024
Independent Director · since 2024
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||